Name of this trial: DAWN-303
What type of cancer is this for? Metastatic pancreatic cancer
Who is this trial for? Patients who have not had any treatment for metastatic pancreatic disease.
What biomarkers are involved? KRAS G12D
What is the National Clinical Trial #? NCT07522073
Brief summary of this trial: Randomized, double-blinded, Ph. 3 trial of chemotherapy with or without INCB161734 in previously untreated, KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma.
Need to know: No systemic treatment for metastatic disease. Prior treatment for nonmetastatic disease is OK if last treatment was administered greater than 6 months prior to study enrollment.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@thechc.com
Name of this trial: AndroMETa-PDAC-288
What type of cancer is this for? Metastatic pancreatic cancer
Who is this trial for? Patients who have not had any treatment for metastatic pancreatic disease.
What biomarkers are involved? N/A
What is the National Clinical Trial #? NCT07490301
Brief summary of this trial: Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma
Need to know: Can not have had any prior radiation, surgery, or systemic treatment for metastatic disease. Prior adjuvant treatment is OK if it has been at least 12 months.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@thechc.com
Name of this trial: TRIDENT
What type of cancer is this for? Pancreatic Adenocarcinoma
Who is this trial for? Subjects With Previously Untreated Metastatic Pancreatic Adenocarcinoma
What biomarkers are involved? N/A
What is the National Clinical Trial #? NCT07259317; https://clinicaltrials.gov/study/NCT07259317
Brief summary of this trial: Phase 2, single arm trial of Relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma
Need to know: Must have histologic diagnosis or cytologic diagnosis of pancreatic adenocarcinoma (PDAC); initial diagnosis of metastatic disease occurred ≤6 weeks prior to enrollment in the study. Must not have received prior systemic anticancer therapy to treat metastatic disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@thechc.com
Name of this trial: MountainTap-30
What type of cancer is this for? Pancreatic Cancer
Who is this trial for? Patients with treatment naïve metastatic pancreatic cancer
What biomarkers are involved? MTAP deletion
What is the National Clinical Trial #? NCT07076121 https://clinicaltrials.gov/study/NCT07076121?term=NCT07076121&rank=1
Brief summary of this trial: A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
Need to know: Patients must not have received any treatment in the metastatic setting. Must have MTAP deletion which will be verified through central testing.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@thechc.com